The relationship between big pharma and the UK turned south this year. Companies like Eli Lilly and Bristol Myers Squibb want the NHS to pay more for drugs, and others are playing hardball by pulling investments and sharply criticizing the government. And every action is wrapped up in the companies' “most favored nation” negotiations with the Trump administration. Ahead of the Financial Times’ Global Pharma and Biotech Summit, held in partnership with Endpoints, Financial Times global pharmaceutical editor Hannah Kuchler joins Post Hoc Live to offer the view from her side of the pond on how the UK and Europe are reacting to pharma's shifting global politics.

Ver todos los episodios